Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, Zanubrutinib, and Lenalidomide in R/R DLBCL
NCT05392257Phase 2Unknown
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05392257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392257.